TRT and Prostate Health: What Testosterone Does to PSA, BPH, and Cancer Risk (2026 Guide)

Executive Summary

Of all the fears that keep men from starting TRT, prostate cancer is the most persistent — and the most based on outdated science. For nearly four decades, the medical community operated on the assumption that testosterone "fed" prostate cancer, largely traced back to a single 1941 case report by Charles Huggins showing that castration reduced prostate cancer progression. That finding — which earned Huggins a Nobel Prize — was correctly interpreted as evidence that androgens stimulate prostate cancer growth. The incorrect extrapolation was that giving testosterone must therefore cause or accelerate prostate cancer.

That extrapolation has been substantially revised. The TRAVERSE trial (2023) — the largest randomized controlled trial ever conducted on testosterone therapy, with 5,246 men followed for a median of 33 months — found no statistically significant increase in prostate cancer incidence in men receiving TRT compared to placebo. Current American Urological Association (AUA) guidelines reflect this shift: TRT is no longer categorically contraindicated in men with a history of treated prostate cancer in appropriate clinical scenarios.

That does not mean prostate concerns are irrelevant. PSA can rise with TRT. Men with active or suspected prostate cancer remain absolute contraindications. BPH (benign prostatic hyperplasia) symptoms require monitoring. But the clinical conversation has fundamentally changed — and men deserve to understand what the evidence actually shows rather than having therapy withheld based on a decades-old assumption. For the complete TRT safety overview, see TRT side effects. For the full protocol framework, see how to build a TRT protocol.

At-a-Glance Comparison

How the clinical understanding of testosterone and prostate health has evolved. Based on TRAVERSE 2023, T-Trials, AUA 2022/2024 guidelines, and the Saturation Model. Updated March 2026.

The TRAVERSE trial and what it actually showed about prostate cancer risk

Men searching does testosterone cause prostate cancer deserve the current clinical answer — not the 1941 case report that defined the field for 80 years. Buyers searching for trt and prostate usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE (TRAVERSE) trial was published in the New England Journal of Medicine in 2023 and represents the largest cardiovascular safety and efficacy study ever conducted on TRT. Among its pre-specified secondary endpoints was prostate safety — including prostate cancer incidence.

Key TRAVERSE prostate findings:
— Prostate cancer incidence: 11.5 events per 1,000 person-years in the TRT group vs 10.7 per 1,000 person-years in the placebo group. Relative risk approximately 1.07 with confidence intervals crossing 1.0. No statistically significant increase.
— High-grade prostate cancer (Gleason ≥7): Numerically slightly higher in the TRT arm, but not statistically significant — and possibly explained by detection bias (more PSA surveillance in TRT-treated men leading to more biopsies and diagnoses).
— PSA rises: As expected, TRT produced PSA increases in the first several months that stabilized — a reflection of prostate filling to physiologic androgen levels, not malignant growth.
— Urinary safety: No significant difference in urinary symptom progression between TRT and placebo arms.

The TRAVERSE findings are consistent with earlier observational data and with the Testosterone Trials (T-Trials) — a coordinated set of seven placebo-controlled trials in older hypogonadal men — which also found no significant increase in prostate cancer or high-grade prostate-specific antigen events.

The current scientific consensus is that TRT titrated to physiologic levels in appropriately screened men does not meaningfully increase prostate cancer risk. This does not mean prostate monitoring is unnecessary — it means the risk profile of TRT relative to prostate cancer has been substantially revised downward from historical estimates. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: men are denied TRT by providers still operating on Huggins-era assumptions — or men self-treat with supraphysiologic doses assuming the prostate risk is a myth, when the evidence supports physiologic TRT as safe but not supraphysiologic androgen exposure. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

The Saturation Model: why the dose-response assumption was wrong

Understanding trt prostate cancer risk requires understanding why the assumed linear relationship between testosterone and prostate stimulation has been largely overturned. Buyers searching for trt and prostate usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The Saturation Model — developed by urologist Abraham Morgentaler and published in a series of papers beginning in 2009 — provides the mechanistic framework for why physiologic TRT does not appear to meaningfully increase prostate cancer risk even though castration demonstrably reduces it.

The core insight: Androgen receptors in prostate tissue become saturated at relatively low testosterone levels — approximately 150–250 ng/dL, which is below the hypogonadal threshold. Once receptors are saturated, additional testosterone does not produce additional prostate stimulation. The prostate is already receiving maximum androgenic signaling at low-normal testosterone levels.

This model explains several previously puzzling clinical observations:
— Hypogonadal men have higher rates of high-grade prostate cancer than eugonadal men — directly opposite to what the Huggins extrapolation predicted. If more testosterone caused more cancer, hypogonadal men should have the lowest rates. They don't.
— Men receiving TRT to normal physiologic range don't show dose-dependent PSA increases beyond the initial plateau — as would be expected if the prostate responded linearly to testosterone.
— Prostate cancer rates in older men (who have lower testosterone) are higher than in younger men (who have higher testosterone) — again, opposite to the assumed relationship.

Supraphysiologic testosterone levels (as used in performance-enhancing contexts — well above the 1,200 ng/dL top of normal range) are a different matter. The Saturation Model doesn't necessarily apply at pharmacologic doses. TRT titrated to physiologic range (typically targeting 400–700 ng/dL) operates within the saturation envelope. Physiologic TRT ≠ pharmacologic androgen use. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: men conflate standard TRT protocols with the androgen exposure seen in performance-enhancing contexts — and either refuse TRT based on steroid-user data, or assume all androgen concerns are myths and pursue supraphysiologic dosing without appropriate prostate monitoring. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Understanding PSA on TRT: what's normal, what warrants workup, and what the AUA guidelines say

Men starting TRT need a working understanding of testosterone and PSA — because PSA will likely rise, and conflating expected changes with pathological signals creates unnecessary panic and unnecessary treatment pauses. Buyers searching for trt and prostate usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Prostate-specific antigen (PSA) is an enzyme produced by prostate epithelial cells. Testosterone is a trophic hormone for prostate tissue — it maintains prostate size, function, and secretion. When hypogonadal men start TRT, the prostate effectively undergoes a restoration of androgen-driven function. This produces a predictable PSA rise in the first 3–6 months, followed by stabilization.

Expected PSA kinetics on TRT:
— Initial rise: 0.3–0.5 ng/mL on average in the first 3–6 months
— Stabilization: PSA typically plateaus by 6–12 months and does not continue rising
— Clinically significant rise threshold (AUA guidelines): a PSA increase of >1.4 ng/mL from baseline in the first 12 months, or a PSA velocity of >0.75 ng/mL per year after the first year, warrants urology referral

Baseline requirements before starting TRT:
1. Baseline PSA measurement before starting TRT
2. Digital rectal exam (DRE) — or documented clinical decision not to perform based on patient context
3. PSA recheck at 3–6 months after starting TRT
4. Annual PSA surveillance thereafter

Absolute contraindication: active or suspected prostate cancer. Any PSA >4.0 ng/mL at baseline, or PSA 2.5–4.0 ng/mL combined with a suspicious DRE, warrants urology referral and prostate cancer workup before initiating TRT. In men with elevated risk (African American, first-degree relatives with prostate cancer before 65), lower thresholds for referral are appropriate.

After treated prostate cancer: The historical absolute contraindication has been nuanced. The 2022 AUA Guideline update acknowledges a growing evidence base for carefully selected patients with treated localized prostate cancer who have undetectable PSA, adequate post-treatment surveillance interval (typically 1–2 years), and low-risk pathology. This requires shared decision-making with a urologist — not a routine TRT clinic decision. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: men panic when PSA rises on TRT and either discontinue effective therapy unnecessarily, or conversely don't have baseline PSA measured before starting and miss an existing prostate cancer that TRT monitoring would have surfaced earlier. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

TRT and BPH: managing benign prostatic hyperplasia and urinary symptoms

Men with urinary symptoms asking about testosterone and prostate often wonder whether TRT will make their BPH worse. The evidence is more nuanced than the historical prohibition suggested. Buyers searching for trt and prostate usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Benign prostatic hyperplasia (BPH) is a non-malignant enlargement of the prostate that causes lower urinary tract symptoms (LUTS) — including urgency, frequency, weak stream, and nocturia. Historically, significant LUTS was considered a relative contraindication to TRT. The current evidence is more nuanced.

What studies show:
— TRAVERSE found no significant difference in urinary symptom progression between TRT and placebo.
— Testosterone has complex effects on the lower urinary tract: it modulates smooth muscle function, nitric oxide signaling in the bladder and urethra, and metabolic factors that influence prostate growth independently of androgen signaling.
— Obesity and metabolic syndrome — both associated with hypogonadism — contribute to prostate inflammation and LUTS through androgen-independent pathways. TRT-driven improvements in body composition may partially offset any androgen-driven LUTS contribution.

Current clinical guidance by IPSS severity:
— Mild BPH (IPSS 1–7): TRT generally safe with baseline documentation and symptom monitoring
— Moderate BPH (IPSS 8–19): Proceed with caution; baseline assessment helpful; close symptom monitoring; coordinate with urology if PSA or DRE is abnormal
— Severe BPH (IPSS ≥20): Urology workup before initiating TRT; consider treating LUTS first with alpha-blockers or 5-alpha reductase inhibitors

5-alpha reductase inhibitors (finasteride, dutasteride): Commonly used for BPH, they also substantially reduce DHT and slow BPH progression. Men on TRT who develop LUTS may benefit from adding a 5-ARI — which also provides hair protection if AGA is a concern (see testosterone and hair loss). Note: 5-ARIs suppress PSA by approximately 50%, which must be factored into PSA thresholds. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: men with pre-existing BPH are told TRT is absolutely off-limits when in reality moderate BPH with proper monitoring and potentially 5-ARI co-prescription is increasingly supported — and leaving hypogonadism untreated has its own health consequences. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

TRT after prostate cancer: what 2022 AUA guidelines actually allow

The question of TRT after prostate cancer is one of the most rapidly evolving areas in men's health — and many survivors have been told they can never use TRT based on guidelines that have since been updated. Buyers searching for trt and prostate usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The 2022 AUA Guideline on Testosterone Deficiency represents a significant shift from the absolute prohibition that governed this space for decades. The current position: TRT may be considered for select patients with a history of treated low-risk to intermediate-risk localized prostate cancer, under the following conditions:

1. Definitive local therapy completed (radical prostatectomy, radiation therapy, brachytherapy) with curative intent
2. Undetectable or stable PSA nadir at or below treatment-specific threshold (e.g., PSA <0.2 ng/mL post-prostatectomy; PSA <2.0 ng/mL + nadir post-radiation)
3. Adequate post-treatment surveillance interval — typically 1–2 years of stable follow-up without evidence of biochemical recurrence
4. Shared decision-making with the treating urologist/oncologist — this is not a decision made at a general TRT clinic without specialist input
5. Intensive ongoing PSA monitoring — more frequent than standard TRT surveillance

What remains an absolute contraindication: Active, untreated, or metastatic prostate cancer. Any man with ongoing androgen deprivation therapy (ADT) as part of cancer treatment cannot receive TRT — ADT and TRT are directly therapeutically opposed.

Active surveillance for low-risk prostate cancer: The situation for men on active surveillance (watchful waiting for Gleason 6 / Grade Group 1 disease) is emerging and individualized. Some urologists have managed patients on active surveillance with TRT and intensive monitoring without apparent biochemical progression, but this remains non-standard and requires a urologist experienced with this approach.

Practical reality: Most TRT clinics and telehealth platforms will not prescribe TRT to a prostate cancer survivor without documented specialist clearance — appropriately so. Men in this situation need their urologist or radiation oncologist involved in the TRT decision, not a telehealth prescriber making the call unilaterally. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: prostate cancer survivors with significant hypogonadal symptoms — a common consequence of both ADT and prostate surgery — are permanently denied quality-of-life improvements that updated guidelines may permit, because neither their oncologist nor primary care physician is aware that the absolute prohibition has been revised. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Pre-TRT prostate workup and ongoing monitoring: the practical checklist for choosing a provider

The most important thing men can do before starting TRT is verify their provider is running a proper prostate surveillance protocol. Many telehealth platforms underinvest in this area. Buyers searching for trt and prostate usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

A responsible TRT provider will complete the following prostate workup and monitoring protocol — defined by the AUA, Endocrine Society, and American Society for Reproductive Medicine (ASRM).

Before starting TRT:
1. Baseline PSA measurement — required for men ≥40, or younger men with elevated risk
2. Digital rectal exam (DRE) — to identify nodules, asymmetry, or abnormal findings
3. Urinary symptom review — AUA IPSS questionnaire to document baseline LUTS severity
4. Absolute contraindication screen — confirm no active or suspected prostate cancer

At 3–6 months after initiating TRT:
1. Repeat PSA measurement
2. Clinical review of urinary symptoms
3. If PSA rise >1.4 ng/mL from baseline, or DRE abnormality: urology referral before continuing

Annually thereafter:
1. Annual PSA and clinical assessment
2. Urology referral for: PSA >4.0 ng/mL, rapid velocity (>0.75 ng/mL/year), new DRE abnormality, or worsening LUTS

Questions to ask your TRT provider:
— What is your PSA monitoring protocol?
— Do you require a baseline PSA before prescribing?
— What happens if my PSA rises more than 1.4 ng/mL in the first year?
— Do you coordinate with urology for elevated PSA findings?

Providers who cannot clearly answer these questions are not running appropriate prostate surveillance. For a full provider comparison including clinical monitoring quality, see best online TRT clinics compared. For cost context including lab work, see how much does TRT cost. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: telehealth TRT platforms that compete on speed and convenience compress or eliminate baseline PSA requirements — meaning men start TRT with undiagnosed prostate cancer whose monitoring then masks the signal. This is a real patient safety concern. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

The prostate evidence has changed significantly — but your TRT provider's monitoring protocol matters as much as the prescribing decision itself. Use our provider comparison tool to find clinics that include baseline PSA, defined monitoring thresholds, and urology referral pathways — not just fast prescribing.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

Does TRT cause prostate cancer?

Current evidence, including the TRAVERSE trial (2023) — the largest TRT RCT ever conducted — found no statistically significant increase in prostate cancer incidence in men receiving TRT compared to placebo over a median 33-month follow-up. The Saturation Model explains why physiologic TRT does not appear to meaningfully increase prostate cancer risk even though castration reduces prostate cancer growth: androgen receptors in prostate tissue become saturated at low-normal testosterone levels, meaning additional testosterone does not proportionally stimulate the prostate. TRT titrated to physiologic range carries a different risk profile than the Huggins-era assumption predicted.

Will my PSA go up on TRT?

Likely yes — in the first 3–6 months, PSA typically rises 0.3–0.5 ng/mL as the prostate restores to physiologic androgen-driven function and then stabilizes. This is an expected restoration effect, not a cancer signal in most cases. The AUA threshold that warrants urology referral is a PSA rise >1.4 ng/mL from baseline in the first 12 months, or a velocity >0.75 ng/mL per year after year one.

Can I start TRT if I've been treated for prostate cancer?

Possibly — the 2022 AUA Testosterone Deficiency Guideline revised the historical absolute prohibition. Carefully selected patients with treated low-to-intermediate-risk localized prostate cancer, undetectable PSA at nadir, adequate post-treatment surveillance interval, and urologist co-management may be considered for TRT via shared decision-making. This requires specialist involvement — not a telehealth TRT clinic decision. Active, untreated, or metastatic prostate cancer remains an absolute contraindication.

What PSA level is too high to start TRT?

Current AUA guidance: PSA >4.0 ng/mL at baseline warrants urology referral and prostate cancer workup before initiating TRT. PSA 2.5–4.0 ng/mL combined with an abnormal DRE or elevated risk profile (African American, first-degree relative with prostate cancer before 65) also warrants referral. These are not hard stops on ever starting TRT — they are indications to rule out prostate cancer first.

Does TRT make BPH worse?

The evidence is mixed but less alarming than the historical prohibition suggested. TRAVERSE found no significant difference in urinary symptom progression between TRT and placebo. For men with mild-to-moderate BPH, TRT with close monitoring and potentially 5-alpha reductase inhibitor co-prescription is increasingly supported. Men with severe BPH (IPSS ≥20) should address urinary symptoms before starting TRT.

Do I need a DRE (digital rectal exam) before starting TRT?

Current AUA guidelines recommend a digital rectal exam (DRE) as part of the baseline prostate evaluation before TRT. Some providers document a clinical decision to defer DRE in younger, lower-risk men, but baseline PSA is always required. If your TRT provider is not checking baseline PSA, they are not meeting the standard of care.

How does TRT affect the prostate?

Testosterone is a trophic hormone for the prostate — it maintains prostate size, function, and secretion. In hypogonadal men starting TRT, the prostate typically undergoes partial restoration toward physiologic androgen-dependent size, reflected in a PSA rise that stabilizes. At physiologic TRT doses, ongoing prostate stimulation appears to plateau per the Saturation Model — androgen receptors in prostate tissue saturate at relatively low testosterone levels (~150–250 ng/dL).

What is the TRAVERSE trial and what did it show for prostate health?

TRAVERSE was a 2023 NEJM-published randomized controlled trial of 5,246 men with hypogonadism and cardiovascular risk factors, comparing TRT vs placebo over a median 33-month follow-up. On prostate safety: no statistically significant increase in prostate cancer incidence (RR ~1.07, CI crossing 1.0), no significant difference in high-grade cancer rates after accounting for detection bias, and no significant difference in urinary symptom progression. It is the largest and most rigorous prostate safety data available for TRT to date.

I'm on finasteride for BPH — how does that affect PSA monitoring on TRT?

5-alpha reductase inhibitors (finasteride, dutasteride) suppress PSA by approximately 50%. If you are on these medications, your measured PSA needs to be multiplied by 2 to estimate your true PSA equivalent for cancer screening purposes. Your TRT provider and urologist must both know you are on a 5-ARI and adjust PSA thresholds accordingly. Failing to account for this can create false reassurance from artificially low PSA readings.

At what age should I get a baseline PSA before TRT?

AUA guidelines recommend PSA baseline before TRT for men ≥40. For men with elevated risk — African American descent, or a first-degree relative diagnosed with prostate cancer before age 65 — baseline PSA is appropriate starting at age 35–40. Some specialists advocate baseline PSA before any TRT prescription regardless of age, given the monitoring responsibility that follows.